

**Supplementary Data****Homozygosity Mapping and Whole Exome Sequencing to Detect *SLC45A2* and *G6PC3* Mutations in a Single Patient with Oculocutaneous Albinism and Neutropenia**

Andrew R. Cullinane, Thierry Vilboux, Kevin O'Brien, James A. Curry, Dawn M. Maynard, Hannah Carlson-Donohoe, Carla Ciccone, NISC Comparative Sequencing Program, Thomas C. Markello, Meral Gunay-Aygun, Marjan Huizing and William A. Gahl

**Supplementary Tables****Supplementary Table 1. White blood cell counts in the patient on and off Neupogen® treatment.**

	On therapy	2 days off therapy	Normal Range
Total WBC count (K/ $\mu$ l)	5.48	1.71	3.4-9.6
Absolute neutrophil count (K/ $\mu$ l)	4.379	0.58	1.29-7.5
Neutrophil (%)	79.9	34	38-78
Absolute lymphocyte count (K/ $\mu$ l)	0.822	0.975	0.48-4.9
Absolute monocyte count (K/ $\mu$ l)	0.27	0.54	0.0-1.5
Absolute eosinophil count (K/ $\mu$ l)	0.00	0.00	0.-0.77
Absolute basophil count (K/ $\mu$ l)	0.0	0.00	0..29

\* WBC – White Blood Cell

\*\* K/ $\mu$ l – Thousands of cells per microliter

**Supplementary Table 2. Whole blood and immunological analysis**

	Patient Values	Normal Range
ALT (U/L)	19	6-41
Complement C3 (mg/dL)	154	69-175
Complement C4 (mg/dL)	24	13-38
Hematocrit (%)	36	31.8-43.2
Hemoglobin (mg/dL)	12.9	11.1-15.0
IgG subclasses 1-4	normal	-
Lymphocyte B-cell defects	normal	-
Lymphocyte phenotyping TBNK	normal	-
Platelets (K/uL)	21	162-380
Prothrombin time (s)	13.3	11.8-14.7
Reticulocyte (%)	1.49	0.66-2.47
Reticulocyte count (K/uL)	60.0	31.7-104.6
Serum creatinine (mg/dL)	0.8	0.7-1.3
Serum sodium (mmol/L)	139	135-144
Total bilirubin (mg/dL)	0.6	0.1-1.0
Total IgA (mg/dL)	88	91-499
Total IgG (mg/dL)	1170	642-1730
Total IgM (mg/dL)	104	34-342

\* K/ $\mu$ l – Thousands of cells per microliter

**Supplementary Table 3. Filtered gene variants within known homozygous regions of the patient.**

Chromosome	Genome Position		Gene	Mutation Type	Reference	Allele		Patient	Amino Acid			CDPred Score
	Left	Right				Variant	Reference		Variant	Position		
5	33990267	33990269	SLC45A2	Frameshift (Stop)	A	-	--	A	PfsX68	330	-30	
17	39508724	39508726	G6PC3	Stop	C	T	TT	Q	X	152	-30	
17	42590581	42590583	CDC27	Stop	A	C	CC	L	X	155	-30	
5	35945878	35945880	CAPSL	Non-synonymous	T	C	CC	D	G	124	-11	
19	10684849	10684851	QTRT1	Non-synonymous	C	G	CC	F	L	372	-9	
17	42569603	42569605	CDC27	Non-synonymous	T	C	CC	H	R	608	-8	
4	42287615	42287617	ATP8A1	Non-synonymous	G	A	AA	L	F	165	-6	
17	42569598	42569600	CDC27	Non-synonymous	A	G	GG	F	L	610	-5	
17	42574281	42574283	CDC27	Non-synonymous	T	C	CC	Y	C	495	-4	
17	42569590	42569592	CDC27	Non-synonymous	T	G	GG	L	F	612	-3	
17	42574327	42574329	CDC27	Non-synonymous	A	C	CC	C	G	480	-3	
17	42590633	42590635	CDC27	Non-synonymous	A	C	CC	Y	D	138	-3	
19	11839827	11839829	ZNF439	Non-synonymous	G	T	TT	R	I	315	-3	
19	12724428	12724430	BEST2	Non-synonymous	G	A	AA	R	Q	8	-2	
17	42571160	42571162	CDC27	Non-synonymous	A	C	CC	D	E	548	-1	
17	42574311	42574313	CDC27	Non-synonymous	T	C	CC	N	S	485	-1	
17	42587149	42587151	CDC27	Non-synonymous	A	C	CC	F	V	282	-1	
17	42590596	42590598	CDC27	Non-synonymous	G	C	CC	S	C	150	-1	
17	42571167	42571169	CDC27	Non-synonymous	T	G	GG	Q	P	546	-1	
17	42590651	42590653	CDC27	Non-synonymous	C	T	TT	A	T	132	0	
17	42571170	42571172	CDC27	Non-synonymous	A	G	GG	L	P	545	1	
17	42576284	42576286	CDC27	Non-synonymous	C	T	TT	S	N	378	1	
17	42576316	42576318	CDC27	Non-synonymous	A	C	CC	I	M	367	1	
17	45807774	45807776	EME1	Non-synonymous	A	C	CC	E	D	69	2	
19	9952350	9952352	COL5A3	Non-synonymous	A	T	TT	D	E	859	2	
4	52637817	52637819	SPATA18	Non-synonymous	A	G	GG	K	R	292	2	
4	74672483	74672485	RASSF6	Non-synonymous	A	G	GG	Y	H	107	2	
17	42574294	42574296	CDC27	Non-synonymous	G	C	CC	P	A	491	3	
4	70190004	70190006	UGT2B28	Non-synonymous	G	A	AA	A	T	346	3	

### **Supplementary Table 3 Legend**

The whole-exome data were aligned to USCS human genome build 18, and filtered for known SNPs. Data are sorted by the potential detriment (CD\_Pred) score. Note the two mutations in *SLC45A2* (c.987delA, p.A330PfsX68) and *G6PC3* (c.829C>T, p.Q277X).

### **Supplementary Figure Legends**

#### **Supplementary Figure 1. Homozygous regions in the patient**

- a) SNP data for the patient showing the regions of extended homozygosity (red boxes) on several chromosomes. Normal regions of no-called SNPs are outlined on chromosome 1 and 9 with a green box. The middle of the B allele plots represents heterozygosity (AB) and the upper and lower edges represent homozygosity (AA or BB).
- b) Table showing actual start and end positions of extended regions of homozygosity. The base positions were determined from USCS genome build 18.

#### **Supplementary Figure 2. Coomassie and silver stained gels**

- a) Coomassie stained polyacrylamide gel of conditioned medium and lysates from control and patient cells. The same pattern and intensity of bands can be seen for both control and patient lanes.
- b) Silver stained gel from a, showing same pattern and intensity of bands for both control and patient's condition media.



